Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT05840302Recruiting
Pain education program to increase activity in chronic low back pain
This trial studies whether teaching “pain neuroscience” (how pain works in the body and brain) helps people with long-term low back pain move more. It compares an education program as part of a multidisciplinary rehab to usual care during your planned hospital stay.
Lamalou-les-BainsAges 18 years+ - NCT05841732Recruiting
Behavior program with exercise to prevent low back pain returning
This trial tests a phone-based behavior change exercise program to help stop low back pain from coming back. It is for people who recently recovered from a recent low back pain episode and can safely do exercises.
Setúbal, Setúbal DistrictAges 18–65 - NCT05846789RecruitingPhase 2
Chemotherapy with or without tocilizumab for breast cancer
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
Atlanta, GeorgiaAges 18 years+ - NCT05847348RecruitingPhase 3
PET scan for rising PSA after prostate cancer treatment
This Phase 3 trial tests whether a special PET scan using 68Ga-PSMA-11 can detect prostate cancer that has returned after surgery or radiation, measured by rising PSA. If the scan works well, it may help doctors find where the cancer is coming back.
BeijingAges 18 years+ - NCT05847569RecruitingPhase 2
Testing alternating doses of belantamab for hard-to-treat myeloma
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
Jacksonville, FloridaAges 18 years+ - NCT05851196Recruiting
Personalized exercise for recurrent low back pain
This study looks at how back muscle features can help tailor an exercise program for people with recurring, non-specific low back pain. It may help by matching exercises to your specific back function and symptoms.
DiepenbeekAges 18–60 - NCT05855811RecruitingPhase 2
Preventing a Second Cancer After Your First Cancer
This Phase 2 trial tests dostarlimab, an immune-based medicine, to help lower the chance of getting a second (new) cancer after treatment for a first solid tumor. It’s for people with higher risk features, and it aims to see whether the drug can prevent or delay second cancers.
CaenAges 18 years+ - NCT05860569RecruitingPhase 1
Gene therapy safety study for inherited high triglycerides and pancreatitis
This Phase 1 trial tests the safety of a gene therapy for people with inherited, hard-to-control high triglycerides (fat in the blood) who have had pancreatitis episodes. It may help by targeting the genes involved in triglyceride control, but the main goal here is to check safety and tolerability.
Beijing, Beijing MunicipalityAges 18–60 - NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT05862337RecruitingPhase 3
New immune plus anti-cancer pills to prevent liver cancer returning
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Bengbu, AnhuiAges 18–75 - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05866783Recruiting
Blood test to predict cancer coming back after liver transplant
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
GhentAges 18 years+ - NCT05868928Recruiting
MRI study of brain metastasis relapse after focused radiation
This study looks at MRI scan patterns to estimate the risk of brain metastases coming back after stereotactic radiosurgery (such as Gamma Knife or CyberKnife). It mainly helps by finding imaging clues that can guide follow-up after treatment.
SeoulAges 18 years+ - NCT05870423RecruitingPhase 1
Testing PARP inhibitors with peptide radiation for NET
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
Rotterdam, South HollandAges 18 years+ - NCT05877872RecruitingPhase 3
Smaller surgery after chemotherapy for recurring nasopharyngeal cancer
This trial tests whether doing a smaller surgery (after chemotherapy works well) can control recurring nasopharyngeal cancer while reducing treatment burden. It is for people whose cancer can be removed by surgery and who respond to an initial course of chemotherapy plus immunotherapy (or another targeted regimen).
Guangzhou, GuangdongAges 18–75 - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT05892744RecruitingPhase 4
Testing brain scans to help choose depression treatment
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
Austin, TexasAges 18–65 - NCT05894070Recruiting
Using your voice recordings to spot cancer coming back
This study looks at whether changes in your voice can help detect early return of laryngeal or hypopharyngeal cancer. If you’ve finished curative treatment and are disease-free for a certain period, your voice will be monitored to see if it can signal recurrence sooner.
BernAges 18 years+ - NCT05900895RecruitingPhase 1
Estradiol plus olaparib for ER-positive breast cancer
This early-stage study tests whether combining estradiol (a form of estrogen) with olaparib (a targeted cancer medicine) can control ER-positive, HER2-negative breast cancer that has spread or come back. It may help by attacking cancer cells in a new way after standard hormone-based treatments.
Lebanon, New HampshireAges 18 years+ - NCT05901545RecruitingPhase 1
Test an iodine-labeled drug to map neck lymph nodes
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
Nashville, TennesseeAges 19 years+ - NCT05907694Recruiting
Treatment of stroke from PFO, with or without closure
This study looks at whether treating a history of “cryptogenic” stroke (stroke with no clear cause) using a patent foramen ovale (PFO) closure, plus medical therapy, is better than medical therapy alone. It focuses on people over 60 with a heart shunt seen on an ultrasound of the heart.
Québec, QuebecAges 18 years+ - NCT05910801RecruitingPhase 2
Tafasitamab plus lenalidomide and venetoclax for relapsed lymphoma
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
Rochester, MinnesotaAges 18 years+ - NCT05913960Recruiting
Theta-burst brain stimulation for major depression
This study tests whether an “accelerated intermittent theta-burst” brain stimulation treatment can improve major depressive disorder by affecting brain signaling pathways. You may be a candidate if you have moderate-to-severe depression and can safely undergo brain MRI.
Hangzhou, ZhejiangAges 12–45
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,355 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.